Journals / Journal of Turkish Spinal Surgery / 2015 / Cilt: 26 - Sayı: 4

ETOFENAMATE VE METHYLPREDNİSOLONE' UN OMURİLİK HASARINA ETKİSİ

EFFECTS OF ETOFENAMATE AND METHYLPREDNISOLONE ON SPINAL CORD INJURY

Pages
277–283
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Etofenamate may be a promising agent in the medical treatment of spinal cord injury

📌 3 Key Takeaways

🎯
Objective & Hypothesis:This study evaluates the effects of etofenamate on secondary damage following a spinal cord injury and compares the effects with those of methylprednisolone.
📊
Key Findings & Data:A total of 31 male Wistar-Albino rats were used.
💡
Conclusion & Impact:Etofenamate may be a promising agent in the medical treatment of spinal cord injury
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

This study evaluates the effects of etofenamate on secondary damage following a spinal cord injury and compares the effects with those of methylprednisolone. A total of 31 male Wistar-Albino rats were used. A weight-drop model was utilized for the experimental spinal cord injury and a 50g-cm impact was applied on the spinal cord. Rats were randomly assigned to one of the three study arms (saline, etofenamate 20 mg/kg, methylprednisolone 30 mg/kg). At the sixth hour of injury electrophysiological evaluations were conducted under anesthesia, and then rats were sacrificed for histopathology. Hematoxylin and eosin staining were applied to the specimens and evaluated under light microscopy. Etofenamate revealed more beneficial results in histopathological evaluations when compared with methylprednisolone, but these favorable results have not been confirmed by electrophysiological measurements. Etofenamate may be a promising agent in the medical treatment of spinal cord injury

Özet

Bu çalışma omurilik hasarını izleyen ikincil olaylar üzerine etofenamate' ın etkisini değerlendirmek ve bu etkiyi metilprednizolon etkisi ile karşılaştırmak amacıyla yapılmıştır. Toplam 31 erkek Wistar-Albino sıçan kullanılmıştır. 50g-cm etkili ağırlık düşürme modeli deneysel omurilik hasarı oluşturmak için kullanılmıştır. Sıçanlar üç çalışma koluna randomize olarak ayrılmışlardır (saline, etofenamate 20 mg/kg, metilprednizolon 30 mg/kg). Hasarın 6.saatinde anestezi altında elektrofizyolojik değerlendirme yapılmış ve sonra histopatolojik inceleme için sıçanlar feda edilmiştir. Hematoksilin-eozin boyaması ile ışık mikroskopu altında değerlendirilmiştir. Etofenamate, metilprednizolon ile karşılaştırıldığında histopatolojik olarak daha faydalı bulunmuştur, fakat bu durum elektrofizyolojik olarak doğrulanamamıştır. Etofenamate omurilik hasarının tedavisinde ümit verici olabilir

🔖

Cite This Article

KAZANCI, B., ER, U., SABUNCUOĞLU, H., GÜÇLÜ, B. (2015). ETOFENAMATE VE METHYLPREDNİSOLONE' UN OMURİLİK HASARINA ETKİSİ. Journal of Turkish Spinal Surgery, Cilt: 26 - Sayı: 4, 277–283. https://ajindex.com/articles/205119

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Akhtar AZ, Pippin JJ, Sandusky CB. Animal studies in spinal cord injury: a systematic review of methylprednisolone. Altern Lab Anim 2009; 37: 43-62.
  2. Alberdi E, Sánchez-Gómez MV, Marino A, Matute C. Ca(2+) influx through AMPA or kainate receptors alone is sufficient to initiate excitotoxicity in cultured oligodendrocytes. Neurobiol Dis 2002; 9: 234-243.
  3. Anderson DK, Hall ED, Braughler JM, McCall JM, Means ED. Effect of delayed administration of U74006F (tirilazad mesylate) on recovery of locomotor function after experimental spinal cord injury. J Neurotrauma 1991; 8: 187-192.
  4. Bardakci H, Kaplan S, Karadeniz U, Ozer C, Bardakci Y, Ozogul C, Birincioglu CL, Cobanoglu A. Methylene blue decreases ischemia-reperfusion (I/R)-induced spinal cord injury: an in vivo study in an I/R rabbit model. Eur Surg Res 2006; 38: 482-488.
  5. Bracken MB, Shepard MJ, Hellenbrand KG, Collins WF, Leo LS, Freeman DF, Wagner FC, Flamm ES, Eisenberg HM, Goodman JH, Perot PL, Green BA, Grossman RG, Meagher JN, Young W, Fischer B, Clifton GL, Hunt WE, Rifkinson N. Methylprednisolone and neurological function 1 year after spinal cord injury. Results of the National Acute Spinal Cord Injury Study. J Neurosurg 1985; 63: 704-713.
  6. Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, Eisenberg HM, Flamm E, Leo-Summers L, Maroon J, Marshall LF, Perot PL, Piepmeier J, Sonntag, VKH, Wagner FC, Wilberger JE, Winn HR. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990; 322: 1405-1411.
  7. Bracken MB, Shepard MJ, Collins WF Jr, Holford TR, Baskin DS, Eisenberg HM, Flamm E, Leo-Summers L, Maroon JC, Marshall LF, Perot PL, Piepmeier J, Sonntag VKH, Wagner FC, Wilberger JL, Winn HR, Young W. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study. J Neurosurg 1992; 76: 23-31.
  8. Bracken MB, Shepard MJ, Holford TR, LeoSummers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL Jr, Piepmeier J, Sonntag VK, Wagner F, Wilberger JE, Winn HR, Young W. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 19